Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 0 Master Protocol of Intratumoral Microdoses via CIVO in Solid Tumors
NCT04541108Phase 1Active, not recruiting
- Sponsor
- Presage Biosciences
- Start
- Jul 2021
- Primary completion
- Dec 2031
- Modality
- Immune Checkpoint Inhibitors, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tilatamig samrotecan, rilvegostomig, volrustomig, sabestomig and pembrolizumab in solid tumor, sponsored by Presage Biosciences. Primary endpoint: Quantification of Selected Pharmacodynamic Biomarkers. Started Jul 2021; status: active, not recruiting.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04541108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541108.